Oblenio Bio Secures $62 Million in Latest Series B Funding Round

Oblenio Bio secured $62 million in its latest Series B, adding another data point to the Legal, Regulatory & Compliance funding market.

Oblenio Bio Raises $62 million in Funding

Oblenio Bio Closes $62M Series B Funding. Led by Samantha Truex Oblenio Bio is developing a broad immune reset as a transformative therapy for refractory autoimmune diseases through its T-cell activator LBL-051.

Investors Behind the Funding

The round was backed by Pfizer Ventures. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Oblenio Bio operates in Legal, Regulatory & Compliance. Oblenio Bio's financing adds to recent private-market activity.

Strategic Use of Funds

Use the funds for the initial clinical development of LBL-051, its tri-specific T-cell engager, designed to achieve a broad immune system reset to treat patients suffering from a r.

Looking Ahead

Oblenio Bio Closes $62M Series B Funding

Source reference: original announcement/article.